Affiliation:
1. Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
2. Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
Abstract
Abstract:
Cancers with a high capability for angiogenesis are frequently regarded as being difficult
to treat. Anti-angiogenesis drugs are considered the primary therapy for these types of
cancers. Due to intrinsic or acquired anti-angiogenesis resistance, therapies result in moderate
clinical consequences, despite some hopeful findings. The importance of non-coding RNAs
(ncRNAs) such as microRNAs (miRNAs), long non-coding (lncRNAs), and circular RNAs
(circRNAs) in drug resistance mechanisms in cancer treatment has been discovered in the previous
decade. Anti-angiogenic drug resistance can be influenced by ncRNA dysregulation.
Hence, ncRNAs are potential drug resistance targets for new anti-angiogenic drugs in the inhibition
of angiogenesis in tumors. Furthermore, some ncRNAs can be employed as biomarkers
for anti-angiogenic drug responses and can be used to monitor cancer non-invasively. Combination
treatment approaches, combined with routine anti-angiogenesis and some drugs that target
the ncRNAs causing resistance, can be potential ways to overcome anti-angiogenesis resistance.
For the first time, we explain the mechanisms of anti-angiogenic drug resistance and
the related miRNAs and lncRNAs and their signaling pathways in commonly used antiangiogenic
drugs implicated in this review article. These ncRNAs could be suggestions for targeting
and reducing anti-angiogenic drugs in the future.
Publisher
Bentham Science Publishers Ltd.
Subject
General Health Professions
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献